Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Application
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Approach 1: Commodity flow approach
1.6.3. Volume price analysis (Model 2)
1.6.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Application outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Tissue Engineering Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Advancements in stem cell technology & tissue engineering
3.4.1.2. Rise in the number of clinical studies for regenerative medicine and tissue engineering
3.4.1.3. Increasing tissue engineering research funding
3.4.2. Market restraint analysis
3.4.2.1. High cost of product development
3.4.2.2. Ethical concerns related to stem cell research & tissue engineered product
3.4.2.3. Clinical issues pertaining to development & implementation of stem cell therapies
3.5. Tissue Engineering Market Analysis Tools
3.5.1. Industry Analysis – Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. COVID-19 Impact Analysis
Chapter 4. Tissue Engineering Market: Application Estimates & Trend Analysis
4.1. Global Tissue Engineering Market Application Movement Analysis
4.2. Cord blood & Cell banking
4.2.1. Cord blood & Cell banking market estimates and forecast 2018 to 2030 (USD Billion)
4.3. Cancer
4.3.1. Cancer market estimates and forecast 2018 to 2030 (USD Billion)
4.4. GI/Gynecology
4.4.1. GI/Gynecology therapy market estimates and forecast 2018 to 2030 (USD Billion)
4.5. Dental
4.5.1. Dental market estimates and forecast 2018 to 2030 (USD Billion)
4.6. Skin & Integumentary
4.6.1. Skin & Integumentary market estimates and forecast 2018 to 2030 (USD Billion)
4.7. Urology
4.7.1. Urology market estimates and forecast 2018 to 2030 (USD Billion)
4.8. Orthopedics, Musculoskeletal, & Spine
4.8.1. Orthopedics, Musculoskeletal, & Spine market estimates and forecast 2018 to 2030 (USD Billion)
4.9. Neurology
4.9.1. Neurology market estimates and forecast 2018 to 2030 (USD Billion)
4.10. Cardiology & Vascular
4.10.1. Cardiology & Vascular market estimates and forecast 2018 to 2030 (USD Billion)
4.11. Others
4.11.1. Others market estimates and forecast 2018 to 2030 (USD Billion)
Chapter 5. Tissue Engineering Market: Regional Estimates & Trend Analysis
5.1. Tissue Engineering Market: Share By Region, 2022 & 2030
5.2. North America
5.2.1. SWOT Analysis
5.2.2. North America Tissue Engineering Market, 2018 – 2030 (USD Billion)
5.2.3. U.S.
5.2.3.1. Key Country Dynamics
5.2.3.2. Competitive Scenario
5.2.3.3. Regulatory Framework
5.2.3.4. U.S. Tissue Engineering Market, 2018 – 2030 (USD Billion)
5.2.4. Canada
5.2.4.1. Key Country Dynamics
5.2.4.2. Competitive Scenario
5.2.4.3. Regulatory Framework
5.2.4.4. Canada Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.3. Europe
5.3.1. SWOT Analysis
5.3.2. Europe Tissue Engineering Market, 2018 – 2030 (USD Billion)
5.3.3. UK
5.3.3.1. Key Country Dynamics
5.3.3.2. Competitive Scenario
5.3.3.3. Regulatory Framework
5.3.3.4. UK Tissue Engineering Market, 2018 – 2030 (USD Billion)
5.3.4. Germany
5.3.4.1. Key Country Dynamics
5.3.4.2. Competitive Scenario
5.3.4.3. Regulatory Framework
5.3.4.4. Germany Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.3.5. France
5.3.5.1. Key Country Dynamics
5.3.5.2. Competitive Scenario
5.3.5.3. Regulatory Framework
5.3.5.4. France Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.3.6. Italy
5.3.6.1. Key Country Dynamics
5.3.6.2. Competitive Scenario
5.3.6.3. Regulatory Framework
5.3.6.4. Italy Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.3.7. Spain
5.3.7.1. Key Country Dynamics
5.3.7.2. Competitive Scenario
5.3.7.3. Regulatory Framework
5.3.7.4. Spain Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.3.8. Sweden
5.3.8.1. Key Country Dynamics
5.3.8.2. Competitive Scenario
5.3.8.3. Regulatory Framework
5.3.8.4. Sweden Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.3.9. Norway
5.3.9.1. Key Country Dynamics
5.3.9.2. Competitive Scenario
5.3.9.3. Regulatory Framework
5.3.9.4. Norway Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.3.10. Denmark
5.3.10.1. Key Country Dynamics
5.3.10.2. Competitive Scenario
5.3.10.3. Regulatory Framework
5.3.10.4. Denmark Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.4. Asia Pacific
5.4.1. SWOT Analysis
5.4.2. Asia Pacific Tissue Engineering Market, 2018 – 2030 (USD Billion)
5.4.3. China
5.4.3.1. Key Country Dynamics
5.4.3.2. Competitive Scenario
5.4.3.3. Regulatory Framework
5.4.3.4. China Tissue Engineering Market, 2018 – 2030 (USD Billion)
5.4.4. Japan
5.4.4.1. Key Country Dynamics
5.4.4.2. Competitive Scenario
5.4.4.3. Regulatory Framework
5.4.4.4. Japan Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.4.5. India
5.4.5.1. Key Country Dynamics
5.4.5.2. Competitive Scenario
5.4.5.3. Regulatory Framework
5.4.5.4. India Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.4.6. Australia
5.4.6.1. Key Country Dynamics
5.4.6.2. Competitive Scenario
5.4.6.3. Regulatory Framework
5.4.6.4. Australia Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.4.7. Thailand
5.4.7.1. Key Country Dynamics
5.4.7.2. Competitive Scenario
5.4.7.3. Regulatory Framework
5.4.7.4. Thailand Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.4.8. South Korea
5.4.8.1. Key Country Dynamics
5.4.8.2. Competitive Scenario
5.4.8.3. Regulatory Framework
5.4.8.4. South Korea Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.5. Latin America
5.5.1. SWOT Analysis
5.5.2. Latin America Tissue Engineering Market, 2018 – 2030 (USD Billion)
5.5.3. Brazil
5.5.3.1. Key Country Dynamics
5.5.3.2. Competitive Scenario
5.5.3.3. Regulatory Framework
5.5.3.4. Brazil Tissue Engineering Market, 2018 – 2030 (USD Billion)
5.5.4. Mexico
5.5.4.1. Key Country Dynamics
5.5.4.2. Competitive Scenario
5.5.4.3. Regulatory Framework
5.5.4.4. Mexico Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.5.5. Argentina
5.5.5.1. Key Country Dynamics
5.5.5.2. Competitive Scenario
5.5.5.3. Regulatory Framework
5.5.5.4. Argentina Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.6. MEA
5.6.1. SWOT Analysis
5.6.2. MEA Tissue Engineering Market, 2018 – 2030 (USD Billion)
5.6.3. South Africa
5.6.3.1. Key Country Dynamics
5.6.3.2. Competitive Scenario
5.6.3.3. Regulatory Framework
5.6.3.4. South Africa Tissue Engineering Market, 2018 – 2030 (USD Billion)
5.6.4. Saudi Arabia
5.6.4.1. Key Country Dynamics
5.6.4.2. Competitive Scenario
5.6.4.3. Regulatory Framework
5.6.4.4. Saudi Arabia Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.6.5. UAE
5.6.5.1. Key Country Dynamics
5.6.5.2. Competitive Scenario
5.6.5.3. Regulatory Framework
5.6.5.4. UAE Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
5.6.6. Kuwait
5.6.6.1. Key Country Dynamics
5.6.6.2. Competitive Scenario
5.6.6.3. Regulatory Framework
5.6.6.4. Kuwait Tissue Engineering Testing Market, 2018 – 2030 (USD Billion)
Chapter 6. Competitive Landscape
6.1. Company/Competition Categorization
6.2. Strategy Mapping
6.3. Key company market share analysis, 2022
6.4. Company Profiles/Listing
6.4.1. Zimmer Biomet Holdings, Inc.
6.4.1.1. Overview
6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.1.3. Product Benchmarking
6.4.1.4. Strategic Initiatives
6.4.2. AbbVie (Allergan)
6.4.2.1. Overview
6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.2.3. Product Benchmarking
6.4.2.4. Strategic Initiatives
6.4.3. Becton, Dickinson and Company
6.4.3.1. Overview
6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.3.3. Product Benchmarking
6.4.3.4. Strategic Initiatives
6.4.4. B. Braun
6.4.4.1. Overview
6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.4.3. Product Benchmarking
6.4.4.4. Strategic Initiatives
6.4.5. Integra LifeSciences Corporation
6.4.5.1. Overview
6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.5.3. Product Benchmarking
6.4.5.4. Strategic Initiatives
6.4.6. Organogenesis Holdings Inc.
6.4.6.1. Overview
6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.6.3. Product Benchmarking
6.4.6.4. Strategic Initiatives
6.4.7. Medtronic
6.4.7.1. Overview
6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.7.3. Product Benchmarking
6.4.7.4. Strategic Initiatives
6.4.8. ACell, Inc.
6.4.8.1. Overview
6.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.8.3. Product Benchmarking
6.4.8.4. Strategic Initiatives
6.4.9. Athersys, Inc.
6.4.9.1. Overview
6.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.9.3. Product Benchmarking
6.4.9.4. Strategic Initiatives
6.4.10. Tissue Regenix Group plc
6.4.10.1. Overview
6.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.10.3. Product Benchmarking
6.4.10.4. Strategic Initiatives
6.4.11. Stryker Corporation
6.4.11.1. Overview
6.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.11.3. Product Benchmarking
6.4.11.4. Strategic Initiatives
6.4.12. RTI Surgical, Inc.
6.4.12.1. Overview
6.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.12.3. Product Benchmarking
6.4.12.4. Strategic Initiatives
6.4.13. ReproCell, Inc.
6.4.13.1. Overview
6.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.13.3. Product Benchmarking
6.4.13.4. Strategic Initiatives
6.4.14. Baxter International, Inc.
6.4.14.1. Overview
6.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.14.3. Product Benchmarking
6.4.14.4. Strategic Initiatives
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/